High-Resolution Measurements of Diet-Microbiome Interactions
A legfontosabb adatok
- Ki végzi
- Stanford University
- Hol
- Stanford (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2026. okt.
- Várható befejezés
- 2028. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Inulin
- Low-fiber control breakfast shake
- Atmo Gas-Sensing Capsule
- CapScan Regional Fluid-Sampling Capsule
- A regiszteradat frissítve
- 2026. október 5.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with irritable bowel syndrome (IBS) and healthy adults. It studies how the gut breaks down dietary fiber, using swallowed capsules.
- Életkor
- 18-75 years
- Nem
- All sexes can join.
- A betegség stádiuma
- IBS group: must meet the Rome IV criteria for IBS. Healthy group: no diagnosed long-term gut disorder and no ongoing gut symptoms that need a doctor's check.
- Korábbi kezelés
- No antibiotics, probiotics or prebiotics within 4 weeks before joining. Some stomach and gut medicines must be stopped for a set time before study visits, for example proton-pump inhibitors within 7 days.
- Biomarker vagy leletérték
- IBS group: a past hydrogen/methane breath test on record, enough to assign a breath-test subtype.
A részvétel fő kizáró okai
- Narrowing or blockage of the gut, a gut fistula, or trouble swallowing
- Gut surgery in the past 3 months, or past surgery that changed the gut, such as bowel resection or bariatric surgery
- Pacemaker or other implanted or portable electronic medical device
- Pregnancy or breastfeeding, BMI ≥40 kg/m², or diabetes
- Allergy or intolerance to inulin or other study meal parts
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-75 years
- Able to provide written informed consent
- Able and willing to swallow capsules and complete all study procedures
- For the Healthy cohort: no history of a diagnosed chronic GI disorder and no ongoing GI symptoms warranting clinical evaluation
- For the IBS cohort: meets Rome IV diagnostic criteria for IBS, with a prior clinical hydrogen/methane breath test on record sufficient to assign a breath-test subtype
- Willing and able to complete a virtual (Zoom) screening visit and two in-clinic study visits approximately one week apart
Ki nem vehet részt
- Gastrointestinal surgery within the past 3 months
- Prior gastrointestinal surgery that alters luminal anatomy (e.g., bowel resection or bariatric surgery)
- Radiation enteritis
- Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to enrollment
- Use of proton-pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole [Nexium®]) within 7 days prior to the study procedure
- Use of histamine blockers, motility-altering medications, narcotic analgesics, or anticholinergic medications within 3 days prior to the study procedure
- Use of antiemetics/5-HT3 antagonists, macrolide antibiotics, or 5-HT4-modulating medications within 2 days prior to the study procedure
- Use of antacids (e.g., Gaviscon®, Mylanta®, TUMS) within 1 day prior to the study procedure
- Gastrointestinal fistula
- Dysphagia or other swallowing disorder affecting the ability to swallow food, pills, or capsules
- Known allergy or intolerance to inulin or other study meal components
- Diabetes or use of medications affecting glucose handling
- Known or suspected gastrointestinal stricture or physiological/mechanical gastrointestinal obstruction
- Diverticulitis
- Gastric bezoar
- Pacemaker or other implanted or portable electromechanical medical device
- Pregnancy or breastfeeding
- BMI ≥40 kg/m²
- Current participation in another interventional study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Helyszínek itt: Egyesült Államok
- Stanford UniversityStanford, Egyesült ÁllamokContact: Sean P Spencer, MD, PhDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to characterize regional intestinal fermentation physiology and determine how the response to fermentable dietary fiber differs between healthy individuals and individuals with irritable bowel syndrome (IBS). The study will use ingestible capsule technologies to directly measure intestinal gases and regional microbiome composition following low-fiber and high-fiber meal challenges.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
Does the change in regional intestinal gas levels following a fermentable-fiber challenge differ between participants with IBS and healthy controls? How are regional intestinal gas dynamics associated with microbiome composition, breath gases, serum short-chain fatty acids, glucose dynamics, metabolites, and gastrointestinal symptoms?
Researchers will compare participants with IBS to healthy controls to determine whether intestinal fermentation responses to dietary fiber differ between these populations.
Participants will:
Complete two study visits approximately one week apart. At one visit, participants will receive a low-fiber control meal, and at the other visit, they will receive the same base meal containing 15 g of inulin. The order of the two meals will be assigned at random.
Swallow an Atmo gas-sensing capsule to measure intestinal H2, CO2, and O2 and a CapScan capsule to collect regional intestinal fluid for microbiome analysis.
Undergo serial blood and breath sampling and gastrointestinal symptom assessments during each 8-hour study visit.
Complete stool and urine collections, dietary assessment, and continuous glucose monitoring before and/or after the study visits.
A vizsgálat 2 csoportja
- Healthy controlsA vizsgált kezelés
The Healthy cohort consists of individuals without a diagnosed chronic gastrointestinal disorder or ongoing gastrointestinal symptoms warranting clinical evaluation. Participants complete two study visits approximately one week apart and receive both meal conditions in randomized order: low-fiber control followed by 15 g of inulin, or 15 g of inulin followed by low-fiber control. At each visit, participants consume the assigned standardized breakfast shake with the Atmo gas-sensing capsule at t=0 and ingest the CapScan regional sampling capsule at t=4 hours.
Kezelés: Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule és CapScan Regional Fluid-Sampling Capsule
- Irritable Bowel Syndrome (IBS)A vizsgált kezelés
The IBS cohort consists of individuals who meet Rome IV diagnostic criteria for irritable bowel syndrome. Participants complete two study visits approximately one week apart and receive both meal conditions in randomized order: low-fiber control followed by 15 g of inulin, or 15 g of inulin followed by low-fiber control. At each visit, participants consume the assigned standardized breakfast shake with the Atmo gas-sensing capsule at t=0 and ingest the CapScan regional sampling capsule at t=4 hours.
Kezelés: Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule és CapScan Regional Fluid-Sampling Capsule
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- First-Principles Mapping of Regional Fermentation Physiology in the Human Intestine With Ingestible Capsules
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07856823: ki vehet részt
- A regiszteradat frissítve
- 2026. október 5.